

[Print Preview](#)[Print Preview \(Short version\)](#)[Back To Search](#)

## Medicines and Healthcare Products Regulatory Agency

CERTIFICATE NUMBER : **UK GMP 18807 Insp GMP 15855/7201-0009**

### CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER <sup>(1), (2)</sup>

#### Part 1

Issued following an inspection in accordance with :  
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of United Kingdom confirms the following:

The manufacturer : **FDC LIMITED**

Site address : **B-8, MIDC INDUSTRIAL ESTATE, WALUJ, AURANGABAD, IN-431136, India**

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 111(4) of Directive 2001/83/EC , transposed in the following national legislation:  
The Human Medicines Regulations 2012 (SI 2012/1916)..

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2017-10-09** , it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC <sup>(3)</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

*(1) The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.*

*(2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.*

*(3) These requirements fulfil the GMP recommendations of WHO.*

#### Part 2

Human Medicinal Products

#### 1 MANUFACTURING OPERATIONS

##### 1.1 Sterile products

1.1.1 Aseptically prepared (processing operations for the following dosage forms)

1.1.1.4 Small volume liquids

##### 1.4 Other products or manufacturing activity

|                                                                       |
|-----------------------------------------------------------------------|
| 1.4.2 Sterilisation of active substance/ excipients/ finished product |
| 1.4.2.1 Filtration                                                    |
| 1.4.2.3 Moist heat                                                    |
| <b>1.5 Packaging</b>                                                  |
| 1.5.2 Secondary packaging                                             |
| <b>1.6 Quality control testing</b>                                    |
| 1.6.1 Microbiological: sterility                                      |
| 1.6.2 Microbiological: non-sterility                                  |
| 1.6.3 Chemical/Physical                                               |

Any restrictions related to the scope of this certificate :

| Building | Room | Line/equipment                                                                                                                                | QC testing | Products     |
|----------|------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------|
| N/A      | N/A  | Filling lines ALP2 and ALP3 are within the scope of this certificate; other lines were not inspected and are not covered by this certificate. | N/A        | confidential |

2018-01-23

Name and signature of the authorised person of the Competent Authority of United Kingdom

**Confidential**

**Medicines and Healthcare Products Regulatory Agency**

Tel : **Confidential**

Fax : **Confidential**

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please [click here](#) to get list of NCA's.

Due to the restrictions caused by COVID-19, the period of validity of MIA's, WDA's, GMP and GDP certificates is automatically extended until the end of 2021. On-site inspections will resume as soon as there is a consensus that the period of the public health crisis has passed. The clarifying remark section of individual MIA's, WDA's, GMP and GDP certificates will indicate any exceptions. Competent authorities reserve the right to inspect a manufacturing site should the need arise.

**As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period**

[EMA © 2014. EudraGMDP 6.4.9.2 build 2020/11/18 11:10]